Scholarlink

Objective <p>To describe the clinical findings and report the incidence of patients developing non-infectious intraocular inflammation (IOI) following intravitreal faricimab injections (IVFs).</p> Methods <p>A retrospective review of electronic medical records was conducted for patients receiving faricimab intravitreal injections for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) at Moorfields Eye Hospital, London, United Kingdom, over a 24-month period.</p> Results <p>3985 eyes from 3151 patients were included and underwent a total of 28,535 IVFs (20,982 for nAMD, 7553 for DMO). 57 eyes from 46 patients presented at least one episode of IOI. The 2-year estimated incidence of IOI was 0.20% [95% CI 0.15–0.26] per injection, 1.43% [95% CI 1.08–1.85] per eye and 1.46% [95% CI 1.07–1.94] per patient. Mean visual acuity (VA) was significantly different between the day of IVF (0.48 ± 0.43 logMAR, range: 0–1.8) and the day of IOI diagnosis (0.67 ± 0.52, range: 0–2.3) <i>(p</i> &lt; 0.001). VA after IOI resolution showed no significant difference from baseline (<i>p</i> &gt; 0.99). Intravitreal injections were resumed in 42 eyes. IVFs re-challenge was attempted in 9 eyes, with 5 developing another episode of IOI.</p> Conclusions <p>This study describes one of the largest reported cohorts of IOI cases following faricimab treatment. It confirms that the incidence of IOI is rare and aligns with the rates of IVF-related adverse effects reported in clinical trials and in recent real-world studies. Overall, faricimab demonstrated a favourable safety profile with good prognosis in cases of IOI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical spectrum of intraocular inflammation following faricimab intravitreal injections: evidence from a large real-life cohort in the United Kingdom

  • 期刊论文

  • 发表日期：

    2026年3月14日

查看全文
  • Giuseppe Demarinis,
  • Ian Yeung,
  • Ella Preston,
  • Praveen J. Patel,
  • Josef Huemer,
  • Robin D. Hamilton,
  • Luke Nicholson,
  • William R. Tucker,
  • Andrea Montesel

摘要

Objective

To describe the clinical findings and report the incidence of patients developing non-infectious intraocular inflammation (IOI) following intravitreal faricimab injections (IVFs).

Methods

A retrospective review of electronic medical records was conducted for patients receiving faricimab intravitreal injections for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) at Moorfields Eye Hospital, London, United Kingdom, over a 24-month period.

Results

3985 eyes from 3151 patients were included and underwent a total of 28,535 IVFs (20,982 for nAMD, 7553 for DMO). 57 eyes from 46 patients presented at least one episode of IOI. The 2-year estimated incidence of IOI was 0.20% [95% CI 0.15–0.26] per injection, 1.43% [95% CI 1.08–1.85] per eye and 1.46% [95% CI 1.07–1.94] per patient. Mean visual acuity (VA) was significantly different between the day of IVF (0.48 ± 0.43 logMAR, range: 0–1.8) and the day of IOI diagnosis (0.67 ± 0.52, range: 0–2.3) (p < 0.001). VA after IOI resolution showed no significant difference from baseline (p > 0.99). Intravitreal injections were resumed in 42 eyes. IVFs re-challenge was attempted in 9 eyes, with 5 developing another episode of IOI.

Conclusions

This study describes one of the largest reported cohorts of IOI cases following faricimab treatment. It confirms that the incidence of IOI is rare and aligns with the rates of IVF-related adverse effects reported in clinical trials and in recent real-world studies. Overall, faricimab demonstrated a favourable safety profile with good prognosis in cases of IOI.